⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use

AOD-9604

Also: Advanced Obesity Drug 9604

ðŸ”¬GH Fragment

How It Works

Mimics GH fat-burning domain. Stimulates lipolysis and inhibits lipogenesis by acting on beta-3 adrenergic receptors in fat tissue, without binding to the GH receptor.

Primary Benefits

1Fat loss without GH side effects

Key Studies

AOD-9604 lipolysis stimulation in preclinical models

Ng et al. demonstrate AOD-9604 stimulates lipolysis and inhibits lipogenesis in adipose tissue without affecting IGF-1 or glucose tolerance.

preclinical

AOD-9604 clinical safety six randomized controlled trials

Heffernan et al.: Pooled analysis of 6 RCTs showing AOD-9604 is well-tolerated with a safety profile similar to placebo despite limited efficacy signals.

moderate

AOD-9604 Phase IIb trial short-term fat reduction

12-week Phase IIb trial: 1mg/day AOD-9604 produced 2.6 kg weight loss vs 0.8 kg placebo, with reductions in abdominal fat and improved lipid profiles.

moderate

Safety Notes

Research-only. Received GRAS status from FDA as food supplement ingredient. Banned by WADA. Phase 3 trial discontinued due to insufficient efficacy.

Dosing Protocol

⚠️ For educational purposes only. Not medical advice. Consult a healthcare professional before using any peptide.

RouteSubQ

Dose Range300-500 mcg

FrequencyDaily

TimingMorning fasted

Cycle Length8-12 weeks

BAC Water2 ml / 5mg vial

Take on empty stomach. No effect on blood sugar or IGF-1.

Half-Life Visualization

⏱️ Half-Life: 1h

Plasma concentration over time

Legal Status by Country

🇺🇸USA

Research Only

🇨🇦Canada

Research Only

🇬🇧UK

Unregulated

🇪🇺EU

Unregulated

🇦🇺Australia

FDA/TGA Approved

Last updated: 2026-01 · Laws change frequently. Verify current status in your jurisdiction.

Expected Timeline

Weeks 2-4

Early lipolysis effects, especially in abdominal area

Month 2-3

Noticeable fat reduction in visceral stores; improved metabolic markers

Long-term

Sustained fat loss; may preserve muscle mass better than caloric restriction alone

Side Effects & Incidence

Side Effect	Incidence	Severity
Injection site reaction	~5% of users	mild
Mild nausea	~3% of users	mild

Incidence rates sourced from published clinical trial data where available; otherwise based on community research observations.

Found in 1 Stack

Fat Loss Focus Stack

Maximum fat loss through multi-pathway metabolic optimization

Retatrutide Semaglutide AOD-9604 MOTS-c

Weekly Peptide Research

New studies · vendor alerts · protocol tips

No spam. Unsubscribe anytime. Research use only.